Regenicin (OTCMKTS:RGIN) & Apyx Medical (NASDAQ:APYX) Critical Comparison

Regenicin (OTCMKTS:RGINGet Free Report) and Apyx Medical (NASDAQ:APYXGet Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Institutional & Insider Ownership

0.0% of Regenicin shares are held by institutional investors. Comparatively, 55.3% of Apyx Medical shares are held by institutional investors. 13.1% of Apyx Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Regenicin and Apyx Medical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regenicin 0 0 0 0 N/A
Apyx Medical 0 0 2 0 3.00

Apyx Medical has a consensus target price of $6.17, indicating a potential upside of 353.43%.

Valuation & Earnings

This table compares Regenicin and Apyx Medical’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Regenicin N/A N/A -$640,000.00 N/A N/A
Apyx Medical $52.35 million 0.90 -$18.71 million ($0.54) -2.52

Regenicin has higher earnings, but lower revenue than Apyx Medical.

Profitability

This table compares Regenicin and Apyx Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Regenicin N/A N/A N/A
Apyx Medical -35.75% -54.90% -28.41%

About Regenicin

(Get Free Report)

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.

About Apyx Medical

(Get Free Report)

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets in the United States and internationally. It operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). The company offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. Its Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also develops and manufactures hand pieces for open and laparoscopic procedures; and OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Receive News & Ratings for Regenicin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenicin and related companies with MarketBeat.com's FREE daily email newsletter.